BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Colorectal cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for colorectal cancer: 576 (356 sponsors; 89 newly posted in the last 180 days, 33 stopped in the last 180 days; 42 new-entrant sponsors). Momentum score 9.7, rank 72 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 6, Phase 1 182, Phase 2 223, Phase 3 56, Phase 4 3, N/A 106.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Exelixis EXEL | 6 | P3 3, P1 3 | 2 | 1 |
| GlaxoSmithKline | 11 | P2 7, P1 2, P3 2 | 2 | 1 |
| Pfizer PFE | 11 | P1 5, NA 1, P3 2, P4 1, P2 2 | 3 | 1 |
| Bristol-Myers Squibb BMY | 8 | P1 2, P2 4, P3 2 | 1 | 0 |
| Akeso | 6 | P2 4, P3 2 | 0 | 3 |
| Qilu Pharmaceutical Co., Ltd. | 5 | P3 2, P1 3 | 1 | 0 |
| Genmab GMAB | 4 | P3 2, P2 2 | 2 | 0 |
| Janssen Research & Development, LLC | 4 | P2 1, P3 2, P1 1 | 0 | 1 |
| Merck Sharp & Dohme LLC MRK | 4 | P3 2, P2 2 | 0 | 1 |
| Shanghai JMT-Bio Inc. | 3 | P2 1, P3 2 | 0 | 0 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 3 | P3 2, P2 1 | 1 | 0 |
| Natureceuticals Sdn Bhd new entrant | 2 | P3 2 | 2 | 1 |
| AbbVie ABBV | 10 | P1 5, P2 4, P3 1 | 1 | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 6 | P1 4, P3 1, P2 1 | 1 | 2 |
| Incyte Corporation INCY | 5 | P3 1, P2 2, P1 2 | 1 | 2 |
| Seagen, a wholly owned subsidiary of Pfizer | 5 | P2 3, P3 1, P1 1 | 0 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 4 | P3 1, P2 2, P1 1 | 1 | 0 |
| Genfleet Therapeutics (Shanghai) Inc. | 4 | P2 3, P3 1 | 2 | 0 |
| Shanghai Henlius Biotech | 4 | P2 2, P1 1, P3 1 | 0 | 1 |
| Jiangsu Famous Medical Technology Co., Ltd. | 3 | P3 1, NA 2 | 1 | 1 |
| Amgen AMGN | 2 | P1 1, P3 1 | 0 | 0 |
| EMD Serono Research & Development Institute, Inc. | 2 | P1 1, P3 1 | 0 | 0 |
| Immunophotonics, Inc. | 2 | P3 1, P2 1 | 0 | 0 |
| Innovent Biologics (Suzhou) Co. Ltd. | 2 | P3 1, P2 1 | 1 | 0 |
| Jiangsu HengRui Medicine Co., Ltd. | 2 | P3 1, P2 1 | 1 | 0 |
New-entrant sponsors: Natureceuticals Sdn Bhd.
Recently stopped trials
- NCT04952753 Novartis Pharmaceuticals - terminated: The study was terminated early due to the halt of NIS793 treatment and urgent safety measures issued in July and August 2023, respectively, Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
- NCT05194735 Alaunos Therapeutics - terminated: Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
- NCT06756035 Context Therapeutics Inc. - terminated: The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termi CT-95 in Advanced Cancers Associated With Mesothelin Expression
- NCT06882746 Boehringer Ingelheim - terminated: Sponsor decision A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
- NCT05167448 Elpiscience (Suzhou) Biopharma, Ltd. - terminated: Sponsor's development strategy adjustment. A Study of ES104 in Patients With Metastatic Colorectal Cancer
- NCT04868877 Merus B.V. - terminated: The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-r Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Soli
- NCT06364696 Astellas Pharma Inc - terminated: Company's strategic decision A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
- NCT05358249 Novartis Pharmaceuticals - terminated: Business reasons and not based on any safety concerns. Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- NCT05589597 Enterome - terminated: Sponsor decision to stop recruitment in context of overall EO4010 development goals. Stop of recruitment was not related to any safety conce EO4010 in Previously Treated Metastatic Colorectal Carcinoma
- NCT05124743 Alaunos Therapeutics - terminated: Screening moved into TCR001-201 under Amendment 4 (IRB approved 20 Jan 2023; implemented February 2023). Previously enrolled participants co HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumor
- NCT06091930 Boehringer Ingelheim - terminated: Sponsor decision A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Can
- NCT01329809 Jennerex Biotherapeutics - terminated: Business decision by the sponsor Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
- NCT04844073 Takeda - terminated: Sponsor decision based on limited anti-cancer activity of TAK-186. A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
- NCT04638751 Persephone Biosciences - suspended: Currently no funding to continue study. ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
- NCT06039202 Holy Stone Healthcare Co., Ltd - suspended: Strategy under discussion CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | BeyondBio Inc. | NCT05093907 A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | recruiting | 27 |
| 2026-12 est. | P1/P2 | Rottapharm Biotech | NCT05205330 Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | Refractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Ca | active not recruiting | 107 |
| 2026-12 est. | P1/P2 | A2 Biotherapeutics Inc. | NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | Solid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Small | active not recruiting | 160 |
| 2026-12 est. | P1/P2 | TiumBio Co., Ltd. | NCT05784688 Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | Solid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer | recruiting | 140 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06008054 A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Co | Esophageal Cancer; Gastric Cancer; Colorectal Cancer | recruiting | 376 |
| 2026-12 est. | P2 | AbbVie ABBV | NCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Met | Unresectable Metastatic Colorectal Cancer | active not recruiting | 280 |
| 2026-12 est. | P1/P2 | 858 Therapeutics, Inc. | NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovar | recruiting | 120 |
| 2026-12 est. | P2 | Delcath Systems Inc. DCTH | NCT06607458 Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Appr | Refractory Metastatic Colorectal Cancer | recruiting | 90 |
| 2026-12 est. | P2 | Shandong New Time Pharmaceutical Co., LTD | NCT06722950 Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy | Colorectal Adenoma | not yet recruiting | 120 |
| 2026-12 est. | P1/P2 | Akeso | NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal | recruiting | 230 |
| 2026-12 est. | P1/P2 | One-carbon Therapeutics AB | NCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | Solid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung | recruiting | 43 |
| 2026-12 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Duc | not yet recruiting | 300 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-24 est. | P3 | Shanghai Kechow Pharma, Inc. | NCT06008119 Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Colorectal Cancer Metastatic | recruiting | 165 |
| 2026-12-30 est. | P1/P2 | Astellas Pharma Global Development, Inc. | NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metasta | active not recruiting | 240 |
| 2026-12-30 est. | P2 | Shanghai Henlius Biotech | NCT07106892 Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer | Colorectal Cancer (CRC) | recruiting | 60 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | Chimeric Therapeutics | NCT06055439 A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Neuroendocrine Tumors; Colorectal Cancer; Gastric Cancer | active not recruiting | 135 |
| 2026-12-31 est. | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT06434597 A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | recruiting | 60 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2027-01-01 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06838546 A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer | Advanced Colorectal Cancer | not yet recruiting | 80 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-01-13 est. | P3 | Akeso | NCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | Colorectal Adenocarcinoma | recruiting | 560 |
| 2027-01-25 est. | P1/P2 | Novartis Pharmaceuticals NVS | NCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung | active not recruiting | 344 |
| 2027-01-29 est. | P1/P2 | IDEAYA Biosciences IDYA | NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors | recruiting | 336 |
| 2027-01-31 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07202364 A Study of YL202 in Patients With Advanced Solid Tumors | Non Small Cell Lung Cancer; Colorectal Cancer; Cervical Cancer; Locally Advanced or Metastatic Solid | recruiting | 100 |
| 2027-02 est. | P1/P2 | Lumicell, Inc. | NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Cancer | active not recruiting | 66 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2027-02-01 (month) | PDUFA date (company-disclosed) | pending | ANAPTYSBIO, INC ANAB | PDUFA February 2027 - ANAPTYSBIO, INC |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P1/P2 | Bexion Pharmaceuticals, Inc. | NCT05322590 BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma | Metastatic Colorectal Carcinoma; Neuropathy | active not recruiting | 195 |
| 2026-11 est. | P2 | BioNTech SE BNTX | NCT04486378 A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage I | Colorectal Cancer Stage II; Colorectal Cancer Stage III | active not recruiting | 327 |
| 2026-10-31 est. | P3 | Natureceuticals Sdn Bhd | NCT07669454 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in | Fatigue Related to Cancer Treatment; Colon Cancer | recruiting | 250 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-01 | P1/P2 | Merus B.V. | NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and | terminated | 194 |
| 2026-10 est. | P2 | Vyriad, Inc. | NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Melanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Cancer | active not recruiting | 87 |
| 2026-09-30 est. | P2 | Kahr Bio Australia Pty Ltd | NCT07235293 A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | Colorectal Cancer | recruiting | 90 |
| 2026-09-28 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-S | terminated | 74 |
| 2026-08 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervic | not yet recruiting | 120 |
| 2026-07 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT07044908 TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer | RAS/BRAF Wild Type Colorectal Cancer | recruiting | 72 |
| 2026-06-30 est. | P3 | Taizhou Hanzhong biomedical co. LTD | NCT05652894 A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | active not recruiting | 190 |
| 2026-06-22 est. | P1/P2 | GlaxoSmithKline | NCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Partic | Neoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Cancer | active not recruiting | 14 |
| 2026-06-19 | P2 | Pfizer PFE | NCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorecta | Metastatic Colorectal Cancer | active not recruiting | 108 |
| 2026-06-16 | P3 | Exelixis EXEL | NCT05425940 Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer | Colorectal Cancer | active not recruiting | 901 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "colorectal cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.